Google's services have been blocked in China for several years, but the company still has businesses there, as the tech giant seeks to sell products to Chinese firms in...Technologyread more
Netflix can sustain its lofty valuation only if global subscriber growth can support increasing content spending and debt.Technologyread more
The House voted to table a resolution to start impeachment proceedings against President Donald Trump introduced by Rep. Al Green.Politicsread more
Investors will be watching out for the release of Australian jobs data, set to be at 9:30 a.m. HK/SIN.Asia Marketsread more
The company blamed its Q2 content slate and price increases for the subscriber miss.Technologyread more
IBM's year-over-year revenue has now declined for four quarters in a row. Impact from Red Hat is not yet factored into the company's guidance.Technologyread more
See which stocks are posting big moves after the bell on July 17.Market Insiderread more
"It's clearly doing more harm than good," the "Mad Money" host says. Instead Facebook should buy Square for $70 billion and expand the payments network worldwide.Mad Money with Jim Cramerread more
Silicon Valley workers say they gravitate toward Yang, who is running for president as a Democrat, because of his approach to research and understanding of tech's moral...Technologyread more
Prosecutors in Masschusetts have dropped a criminal case against actor Kevin Spacey, who had been accused of groping an 18-year-old man.Entertainmentread more
"The passport contains numerous ingress and egress stamps, including stamps that reflect use of the passport to enter France, Spain, the United Kingdom, and Saudi Arabia in...Politicsread more
AstraZeneca, which saw off a $120 billion takeover attempt by Pfizer in 2014, said the sale would allow it to focus on developing new medicines in its main areas of cancer, and respiratory and cardiovascular diseases.
The U.S. company, which on Monday bought cancer drug firm Medivation for $14 billion in cash, said the antibiotics would enhance its portfolio of more than 60 anti-infective and anti-fungal medicines.
The medicines include approved antibiotics Merrem, Zinforo and Zavicefta, and ATM-AVI and CXL, which are in clinical development, AstraZeneca said.
Pfizer will pay $550 million upon completion and a further unconditional $175 million in January 2019, AstraZeneca said.
It will also pay up to $250 million in milestone fees, up to $600 million in sales-related payments and recurring, double-digit royalties on future sales of Zavicefta and ATM-AVI in certain markets.
The two established medicines in the deal — Merrem, used to treat serious infections in hospitalized patients, and Zinforo, an intravenous antibiotic used for skin and soft tissue infections and pneumonia — generated sales of $250 million in 2015, AstraZeneca said.
The British company said the agreement did not impact its financial guidance for 2016.
Its shares were trading down 0.2 percent in early deals on Wednesday, broadly in line with the market.